Ultragenyx Pharmaceutical Inc (RARE):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Ultragenyx Pharmaceutical Inc (RARE) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7191
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops life-enhancing therapeutics for rare and ultra-rare genetic diseases. Its only marketed product, Mepsevii (vestronidase alfa) is the first indication approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome). The company’s pipeline comprises Burosumab (KRN23 or UX023), a fully human monoclonal antibody in Phase 3 for the treatment of X-linked hypophosphatemia (XLH); and Burosumab in Phase 2 for the treatment of tumor-induced osteomalacia (TIO); UX007 in Phase 3 for patients with Glut1 DS; UX007 as an oral administration in Phase 2 for the treatment of LC-FAOD. DTX301, in Phase 2 for the treatment of ornithine transcarbamylase (OTC) deficiency; DTX401 in Phase 1 for the treatment of GSDIa, and DTX201 in Phase 1 for the treatment of hemophilia A. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc (RARE) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Ultragenyx Pharmaceutical Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deal Details 10
Ultragenyx Pharmaceutical Amends its Licensing Agreement with St. Jude Children’s Research Hospital 10
Equity Offering 11
Ultragenyx Pharma Plans to Raise up to USD72.6 Million in Public Offering of Shares 11
Ultragenyx Pharma Prices Public Offering of Shares for USD250 Million 12
Ultragenyx Pharmaceutical Inc – Key Competitors 14
Ultragenyx Pharmaceutical Inc – Key Employees 15
Ultragenyx Pharmaceutical Inc – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Ultragenyx Pharmaceutical Inc, Medical Equipment, Key Facts, 2017 2
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Ultragenyx Pharmaceutical Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Ultragenyx Pharmaceutical Inc, Deals By Market, 2012 to YTD 2018 8
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Ultragenyx Pharmaceutical Amends its Licensing Agreement with St. Jude Children’s Research Hospital 10
Ultragenyx Pharma Plans to Raise up to USD72.6 Million in Public Offering of Shares 11
Ultragenyx Pharma Prices Public Offering of Shares for USD250 Million 12
Ultragenyx Pharmaceutical Inc, Key Competitors 14
Ultragenyx Pharmaceutical Inc, Key Employees 15
Ultragenyx Pharmaceutical Inc, Subsidiaries 16

List of Figures
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Ultragenyx Pharmaceutical Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Ultragenyx Pharmaceutical Inc (RARE):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Corning Incorporated:企業の戦略・SWOT・財務情報
    Corning Incorporated - Strategy, SWOT and Corporate Finance Report Summary Corning Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Paliburg Holdings Limited:戦略・SWOT・企業財務分析
    Paliburg Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Paliburg Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CGN Power Co Ltd (1816):企業の財務・戦略的SWOT分析
    CGN Power Co Ltd (1816) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Valiant Holding AG:企業の戦略・SWOT・財務分析
    Valiant Holding AG - Strategy, SWOT and Corporate Finance Report Summary Valiant Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • FLX Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary FLX Bio Inc (FLX Bio) is an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compound, FLX475, blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor m …
  • Cowen Inc:企業のM&A・事業提携・投資動向
    Cowen Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cowen Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Delcath Systems Inc (DCTH):製薬・医療:M&Aディール及び事業提携情報
    Summary Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloods …
  • Health Care Service Corp:企業の戦略的SWOT分析
    Health Care Service Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Clarient Inc-医療機器分野:企業M&A・提携分析
    Summary Clarient Inc (Clarient) is a cancer diagnostic laboratory services provider that provides comprehensive cancer–diagnostic laboratory services. The company provides oncology testing and other diagnostics services. Clarient offers detailed information to characterize and assess cancer for accu …
  • Huegli Holding AG:企業の戦略・SWOT・財務情報
    Huegli Holding AG - Strategy, SWOT and Corporate Finance Report Summary Huegli Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Deluxe Corporation
    Deluxe Corporation - Strategy, SWOT and Corporate Finance Report Summary Deluxe Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cogeco Communications Inc (CCA):企業の財務・戦略的SWOT分析
    Cogeco Communications Inc (CCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Parker Drilling Co (PKD):企業の財務・戦略的SWOT分析
    Parker Drilling Co (PKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Noble Energy, Inc.:企業の戦略・SWOT・財務分析
    Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Shanghai SECCO Petrochemical Co Ltd:企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • VVC Exploration Corp (VVC):企業の財務・戦略的SWOT分析
    Summary VVC Exploration Corp (VVC) is a mining and mineral exploration company. It is involved in acquisition, exploration, and development of gold, copper, silver, and other mineral properties. Its projects portfolio includes Gloria, Cumeral, La Tuna, and Timmins projects. VVC also offers open-pit …
  • FDC Ltd (FDC):企業の財務・戦略的SWOT分析
    Summary FDC Ltd (FDC) is a pharmaceutical company that manufactures and markets of oral rehydration salts, ophthalmics and functional foods. The company also provides active pharmaceuticals ingredients (APIs). It provides products for the therapeutic segments of anti-infectives, gastrointestinals, o …
  • Bankinter, S.A.:企業の戦略・SWOT・財務情報
    Bankinter, S.A. - Strategy, SWOT and Corporate Finance Report Summary Bankinter, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Mid-America Apartment Communities Inc (MAA):企業の財務・戦略的SWOT分析
    Summary Mid-America Apartment Communities Inc (MAA) is a real estate investment company that operates apartment homes. The company is engaged in property development, property management, redevelopment, acquisition, sales, marketing and financing. MAA provides web-based and technology driven support …
  • Dynasil Corporation of America (DYSL):企業の財務・戦略的SWOT分析
    Summary Dynasil Corporation of America (Dynasil) is an electronic equipment company that develops and manufactures optics and photonics products. The company’s products include beam splitters, bandpass filters, coatings, crystal materials, imaging detectors, diffraction gratings, tunable light sourc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆